Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fluzone

(Influenza Virus Vaccine)

Phase 3Vaccine

The flu vaccine helps protect your body from getting infected with the influenza virus, which causes the flu illness with symptoms like fever, cough, and body aches.[1] Fluzone is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]

Fluzone is one of 83 biologic programs targeting Paraganglioma. It is currently in Phase 3.

4

Indications

27

Total Trials

1

Active Trials

82

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParagangliomaActive, not recruiting

AstrocytomaActive, not recruiting

OligodendrogliomaActive, not recruiting

LymphomaRecruiting

ParagangliomaPreclinical

Active, not recruiting

AstrocytomaPreclinical

Active, not recruiting

OligodendrogliomaPreclinical

Active, not recruiting

LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Fluzone

Zofran

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Decadron

QQuince Therapeutics S.p.A.

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

ApprovedRecruiting

Lymphoma

NCT05170399

Clinical

Trials by Indication[1]

Influenza16 trials

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Completed· Sanofi logo

Sanofi·Phase 3·NCT01138397·129 enrolled

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Completed· GSK logo

GSK·Phase 1/2·NCT06382311·991 enrolled

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Completed·IID Biomedical Corporation, Quebec·Phase 3·NCT00232947·900 enrolled

Show 13 more trials

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

Unknown status·IID Biomedical Corporation, Quebec·Phase 3·NCT00216242·7,400 enrolled

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Completed·SSeqirus·Phase 3·NCT00959049·1,474 enrolled

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Completed· Sanofi logo

Sanofi·Phase 2·NCT00845429·729 enrolled

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Completed· Sanofi logo

Sanofi·Phase 2·NCT00946179·130 enrolled

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）

Completed·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 3·NCT01551823·1,200 enrolled

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT00858468·394 enrolled

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)

Completed· Sanofi logo

Sanofi·Phase 3·NCT01121822·129 enrolled

Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy

Completed·SSt. Antonius Hospital·N/A·NCT01000246·50 enrolled

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Completed·IInstitute of Medical Biology, Chinese Academy of Medical Sciences·Phase 3·NCT01551810·1,200 enrolled

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT02649192·87 enrolled

A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population

Completed·SSeqirus·Phase 3·NCT00700193·298 enrolled

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Completed· Novartis logo

Novartis·Phase 3·NCT00464672·1,893 enrolled

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Completed· Novartis logo

Novartis·Phase 2·NCT00264576·613 enrolled

Immunogenicity4 trials

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Completed· Sanofi logo

Sanofi·Phase 4·NCT00390884·173 enrolled

Trial to Collect Safety Data and Sera for Immunogenicity Testing

Completed· Sanofi logo

Sanofi·Phase 4·NCT00389857·31 enrolled

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Completed· Sanofi logo

Sanofi·Phase 4·NCT00836953·33 enrolled

Show 1 more trial

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Completed· Sanofi logo

Sanofi·Phase 4·NCT00389532·116 enrolled

Vaccination1 trial

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001080

Children1 trial

Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine

Completed· Sanofi logo

Sanofi·Phase 4·NCT00258817·30 enrolled

Flu Vaccine1 trial

Study of a Flu Vaccine in Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001127·15,000 enrolled

4 more indications

Infants1 trial

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Completed· Sanofi logo

Sanofi·Phase 3·NCT00885105·242 enrolled

Immune Response1 trial

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Completed· Sanofi logo

Sanofi·Phase 4·NCT00835926·121 enrolled

Elderly Patients1 trial

Vaccine Efficacy in Diabetic and Elderly Patients

Completed·TTulane University··NCT02675608·164 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Influenza Virus Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Influenza Virus Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Influenza Virus Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Related News